The extent to which chronic nicotine treatment can alter the effects of the nicotinic acetylcholine receptor antagonist mecamylamine, and whether those effects can be attenuated by nicotine have not been clearly established in the literature. Here, the discriminative stimulus effects of mecamylamine were compared between one group of rhesus monkeys receiving a continuous infusion of nicotine base (5.6 mg/kg/day subcutaneously) and another group of monkeys not receiving nicotine treatment. Both groups responded under a fixed ratio 5 schedule of stimulus-shock termination. Stimulus control was obtained at doses of 1.78 mg/kg mecamylamine in monkeys receiving continuous nicotine and 5.6 mg/kg mecamylamine in monkeys not receiving continuous nicotine treatment. Nicotine did not attenuate the discriminative stimulus effects of mecamylamine in either group. Discontinuation of continuous nicotine produced responding on the mecamylamine lever within 24 h in some but not all monkeys. This may indicate a qualitative difference in the discriminative stimulus effects of mecamylamine between groups, perhaps reflecting antagonism of nicotine and nicotine withdrawal in monkeys receiving continuous nicotine. The failure of nicotine to reverse the effects of mecamylamine is consistent with a noncompetitive interaction at nicotinic acetylcholine receptors and indicates that mecamylamine-induced withdrawal cannot be readily modified by nicotine. Behavioural Pharmacology 25: [296][297][298][299][300][301][302][303][304][305] Monkeys were seated individually in chairs (Model R001; Primate Products, Miami, Florida, USA) in front of a stainless steel wall with two levers and two lights (i.e. one above each lever) within ventilated, soundattenuating chambers. Their feet were maintained in Mecamylamine discrimination in rhesus monkeys Cunningham et al. 297
Introduction
Laboratory studies on drug dependence and withdrawal involve abrupt discontinuation of chronic drug treatment or administration of a pharmacologically related antagonist during chronic drug treatment. Withdrawal upon abrupt discontinuation of drug treatment has face validity for drug dependence that occurs outside the laboratory. However, the expression and magnitude of withdrawal emerging once drug treatment is discontinued can vary markedly over time between animals (e.g. diazepam; Lukas and Griffiths, 1982) . In contrast, antagonist-induced withdrawal is typically less variable between animals because of a shorter onset and larger magnitude as compared with abrupt discontinuation of chronic drug treatment (e.g. morphine; Woods and Gmerek, 1985) . Withdrawal can be measured by quantifying signs or elicited (i.e. unlearned) behaviors, as well as by disruption of normal physiology or learned behaviors. Drug discrimination assays have been used to assess dependence and withdrawal by training an antagonist as a discriminative stimulus in agonistdependent animals (Li et al., 2011) . Drug discrimination is particularly useful for assessing withdrawal that is not evidenced by robust changes in physiology or unlearned behavior (Stewart and McMahon, 2010) .
For an antagonist to be of use in assessing dependence and withdrawal, it ideally should produce little or no effect in animals that are drug-naive (i.e. not receiving chronic treatment) at the smallest dose that reliably produces withdrawal in agonist-treated animals. The μ-opioid receptor antagonist naloxone produces directly observable signs of withdrawal in morphine-treated animals at doses much smaller than those producing signs in the absence of morphine treatment (Aceto et al., 1997) . The benzodiazepine receptor antagonist flumazenil is also more potent in diazepam-treated monkeys than in monkeys not receiving diazepam treatment (Lukas and Griffiths, 1982) . In addition to quantitative differences, agonist treatment often results in qualitative changes in the effects of an antagonist, which can be detected using drug discrimination assays. In the absence of morphine treatment, pigeons could discriminate naltrexone; however, the training dose was 100-fold higher than the training dose in pigeons receiving 100 mg/kg/day of morphine (Valentino et al., 1983) . Moreover, although various μ-opioid receptor antagonists substituted for the effects of naltrexone in morphine-treated pigeons, substitution for naltrexone in morphine-naive pigeons was not obtained for many of the same antagonists. Similar differences in discriminative stimulus effects, both quantitative and qualitative, were demonstrated for flumazenil in rhesus monkeys receiving 5.6 mg/kg/day of diazepam versus monkeys not receiving diazepam treatment (Gerak and France, 1999) .
Mecamylamine (3-methylaminoisocamphane hydrochloride or Inversine) is a secondary amine that penetrates the central nervous system, which initially garnered interest because of its ability to inhibit the transmission of impulses across autonomic ganglia (Stone et al., 1956) . Mecamylamine is an antagonist of nicotinic acetylcholine receptors (nAChRs; Garcha and Stolerman, 1993; Mariathasan and Stolerman, 1993; Webster et al., 1999) . In binding studies with [3H]mecamylamine and nicotine, mecamylamine did not block nicotine binding but was able to block nicotine-induced seizures, indicating that mecamylamine binds to a different site than nicotine (Banerjee et al., 1990) . Because the interaction between nicotine and mecamylamine is noncompetitive, the effects of mecamylamine are not always reversed or surmounted by nicotine (Stolerman et al., 1983) . Mecamylamine attenuates many of the behavioral effects of nicotine, including its positive reinforcing and aversive effects, its effects on rates of schedule-controlled behavior and locomotor activity (Clarke and Kumar, 1983; Fudala et al., 1985; Reavill and Stolerman, 1990) , and the discriminative stimulus effects of nicotine in mice, rats, and nonhuman primates (Stolerman et al., 1999; Jutkiewicz et al., 2011; Cunningham et al., 2012) . Mecamylamine, however, may have limited selectivity for nicotinic acetylcholine-gated ion channels. For instance, the N-methyl-D-aspartate (NMDA) antagonist phencyclidine and the calcium channel blocker verapamil both have high affinity for [3H]mecamylaminebinding sites, perhaps reflecting binding of mecamylamine at NMDA receptors and calcium channels (Banerjee et al., 1990) . Further, mecamylamine has been reported to antagonize NMDA receptor-mediated norepinephrine release (O'Dell and Christensen, 1988) , as well as to attenuate NMDA-induced lethality (McDonough and Shih, 1995) . Collectively, these data suggest that the effects of mecamylamine may not solely be mediated by nAChRs.
Mecamylamine has been used to assess nicotine dependence and withdrawal. Mecamylamine has been reported to produce a larger number of directly observable and physiological signs in the presence of nicotine treatment compared with the absence of treatment, consistent with antagonist-induced nicotine withdrawal (Watkins et al., 2000; Johnson et al., 2008; Weaver et al., 2012; Harris et al., 2013) . Increased reward thresholds produced by mecamylamine in intracranial self-stimulation assays in nicotine-treated rodents are indicative of a deficit in brain reward function. Moreover, a dose of mecamylamine that increased reward thresholds in nicotine-dependent rats did not exert the same effect in saline-treated rats (Marcinkiewcz et al., 2009 ). However, mecamylamine alone does have effects, as evidenced by its ability to serve as a discriminative stimulus in the absence of nicotine treatment in rats (Garcha and Stolerman, 1993) . Some, but not all, ganglion-blocking drugs substituted for the discriminative stimulus effects of mecamylamine in this study, and the mecamylamine discriminative stimulus was not attenuated by nicotine (Garcha and Stolerman, 1993) .
Here, drug discrimination was used to compare the effects of mecamylamine between one group of rhesus monkeys receiving nicotine treatment (5.6 mg/kg/day continuously) and another group not receiving nicotine treatment. Two hypotheses were tested to examine the extent to which the discriminative stimulus effects of mecamylamine in nicotine-treated monkeys were related to withdrawal. One hypothesis was that mecamylamine would be discriminated in the presence of nicotine treatment at doses smaller than those that could be discriminated in the absence of nicotine treatment. A second hypothesis was that temporary discontinuation of nicotine treatment might result in a time-related increase in withdrawal and a corresponding switch in responding from the lever associated with vehicle, or the absence of withdrawal, to the lever associated with the antagonist, or the presence of withdrawal. Although both hypotheses were to some extent confirmed, other results consistent with a noncompetitive interaction between mecamylamine and nicotine illustrate a limitation of the current approach in assessing the nicotine-withdrawal reversing effects of nAChR drugs.
Methods

Subjects
The study included adult rhesus monkeys (Macaca mulatta) that had no prior drug use or experimental history at the beginning of the experiment. Four male monkeys and one female monkey received continuous nicotine infusion; two male monkeys and two female monkeys did not receive continuous nicotine treatment. The monkeys were housed individually in stainless steel cages on a 14-h light/10-h dark schedule (lights on at 06:00 h). They were maintained at 95% free-feeding weight (range 6-10.5 kg), with a diet consisting of High Protein Monkey Diet (Harlan Teklad, Madison, Wisconsin, USA), fresh fruit, and peanuts; water was continuously available in the home cage. Monkeys were maintained and experiments were conducted in accordance with the Institutional Animal Care and Use Committee, The University of Texas Health Science Center at San Antonio, and the National Institutes of Health's Guide for the Care and Use of Laboratory Animals (Institute for Laboratory Animal Research, 2011). contact with brass electrodes to which a brief electric stimulus (3 mA, 250 ms) could be delivered from an a/c generator (Coulbourn Instruments, Whitehall, Pennsylvania, USA). A MED-PC interface connected the chambers to a computer, which controlled and recorded lever responses with MED-PC software (Med Associates, Inc.; St. Albans, Vermont, USA).
Osmotic minipump and continuous nicotine treatment
Nicotine was administered continuously through an osmotic minipump (Alzet 2ML4; Durect Corp., Cupertino, California, USA) implanted in the midscapular region or the flank. The pH of the nicotine solution was adjusted to 7 with buffer and the concentration was adjusted per individual monkey according to body weight at the time of minipump implantation for a dose of 5.6 mg/kg/day. Every 28 days, the monkeys were given ketamine (10 mg/kg) for immobilization and transportation to the experimental surgery department, where anesthesia was maintained with inhaled isoflurane. At this time, depleted pumps were removed and new, sterile pumps were implanted.
Discrimination training
Responding was maintained under a fixed ratio 5 (FR5) schedule of stimulus-shock termination. Illumination of the lights signaled that an electric stimulus was scheduled for delivery in 10 s; however, five consecutive responses on a lever extinguished the lights, prevented delivery of the electric stimulus, and postponed the schedule for 30 s. The schedule of stimulus-shock termination ended after 10 min or after the delivery of four electric stimuli, whichever occurred first.
Experimental sessions began with a 30-min timeout followed by a 10-min schedule of stimulus-shock termination. The lever designated as correct during training was assigned based on whether the monkey received saline or the training dose of mecamylamine. Mecamylamine lever assignments were balanced across the groups for left and right levers and remained the same for the duration of the study. Five consecutive responses on the correct lever postponed the shock schedule; incorrect responses reset the response requirement. The first test was conducted when for five consecutive or for six of seven training sessions, at least 80% of the total responses occurred on the correct lever and fewer than five responses occurred on the incorrect lever before completion of the first fixed ratio on the correct lever.
Discrimination testing
Test sessions were identical to training sessions, except that five consecutive responses on either lever postponed the schedule of stimulus-shock termination. Further tests were conducted when the performance in consecutive training sessions, including both saline and mecamylamine training sessions, satisfied the test criteria.
To establish a dose-response function, a dose of mecamylamine or hexamethonium was administered at the beginning of a session (i.e. timeout) or 30 min before the schedule of stimulus-shock termination. For tests with nicotine alone, the pretreatment interval was decreased to 10 min before the schedule of stimulus-shock terminationthat is, 20 min after administration of saline. For some tests, immediately after the 10-min schedule of stimulus-shock termination, up to five cycles were added; the subsequent cycles consisted of a 10-min pretreatment followed immediately by 10 min of responding under the schedule of stimulus-shock termination. The combined effects of mecamylamine and nicotine were assessed by administering the training dose of mecamylamine 30 min beforehand, followed by saline or a dose of nicotine 10 min before a subsequent 10-min response period. To examine the duration of action of mecamylamine, saline or 5.6 mg/kg mecamylamine was administered on separate days either at the beginning of or in 100-min intervals before a test session consisting of six cycles. To examine the effects of abrupt discontinuation of nicotine treatment, monkeys were tested on consecutive days with no intervening training and with an injection of saline administered 30 min before a 10-min response period, one day before and each of the next 4 days after the removal of the osmotic minipump containing nicotine.
Drugs
Nicotine hydrogen tartrate salt, hexamethonium bromide (Sigma-Aldrich, St. Louis, Missouri, USA), and mecamylamine hydrochloride (Waterstone Technology, Carmel, Indiana, USA) were dissolved in physiological saline and administered subcutaneously in the midscapular region of the back in volumes of less than 3 ml. Nicotine dose was expressed as the weight of the base only. For both mecamylamine and hexamethonium, doses in mg/kg were expressed as the combined weight of the base and the salt. Ketamine was obtained in a commercial solution of 100 mg/ml (Butler Animal Health Supply, Dublin, Ohio, USA).
Data analyses
Data were expressed per individual monkey or as the mean of the values obtained for individual monkeys. Discrimination data were calculated as the percentage of responses on the mecamylamine lever of the total responses on the saline and mecamylamine levers. The rate of responding on both levers (i.e. mecamylamine and saline) was calculated as responses per second, excluding responses during timeouts. The rate of responding during a test was expressed as the percentage of the control response rate for individual animals. The control was defined as the average response rate for all cycles during the five previous saline training sessions, excluding sessions during which the test criteria were not satisfied.
Discrimination and rate data were averaged among subjects and plotted as a function of dose or time.
Potency of a drug to produce mecamylamine-appropriate responding was calculated by simultaneously fitting straight lines to individual dose-effect data using Prism version 5.0 for Windows (GraphPad; La Jolla, California, USA) with linear regression. Straight lines were fitted to the linear portion of dose-effect curves, defined by doses producing 20-80% mecamylamine-lever responding, including not more than one dose producing less than 20% mecamylamine-lever responding and not more than one dose producing greater than 80% mecamylaminelever responding. Other doses were excluded from the analyses. Doses corresponding to the 50% level of the effect (ED 50 ) and 95% confidence limits were calculated by parallel line analyses of data from individual subjects (Tallarida, 2000) .
The time course of mecamylamine was constructed by combining six-cycle test data obtained on different days and with different pretreatment times. The pretreatment intervals between tests were selected so that the sixth cycle of a test would coincide with the first cycle of a second test; data from these cycles were averaged in individual monkeys for further analysis. Significant changes in the discrimination or response rate over time were analyzed by repeated measures one-way analysis of variance followed by Dunnett's post-hoc test (P < 0.05). When the mean response rate was not decreased to less than 50% at any dose of a drug, significant changes in response rate were examined with linear regression and an F-ratio test comparing the slope to 0. If the slope was not significantly different from 0, then there was no significant effect of the drug on response rate as a function of dose.
Results
The effects of mecamylamine in nicotine-treated monkeys Monkeys receiving 5.6 mg/kg/day nicotine were initially trained with 1 mg/kg mecamylamine. After 24 sessions including both mecamylamine and saline training sessions, the training dose was increased to 1.78 mg/kg mecamylamine. The total number of training sessions (including training at both 1 and 1.78 mg/kg mecamylamine) required for each monkey to pass the test criteria were 121, 125, 128, 160, and 204. In monkeys receiving continuous nicotine treatment, mecamylamine dose-dependently increased the percentage of responses on the mecamylamine lever to 95% at the training dose (1.78 mg/kg subcutaneously; Fig. 1, top  left) , whereas saline produced 1% of responses on the mecamylamine lever (Fig. 1, top left, square) . The ED 50 value (95% confidence limits) of mecamylamine to produce discriminative stimulus effects was 0.82 mg/kg (0.59-1.12 mg/kg). The control rates of responding for individual monkeys were 1.31, 1.50, 1.74, 2.03, and 2.50 responses/s. Mecamylamine did not significantly modify response rate as a function of dose (Fig. 1,  bottom left) .
The effects of mecamylamine in untreated monkeys
After 120 sessions (including both mecamylamine and saline training sessions) of training at the initial training dose (1 mg/kg) of mecamylamine, the training dose was increased to 3.2 mg/kg. After 105 additional training sessions at 3.2 mg/kg, the training dose was increased further to 5.6 mg/kg. Monkeys satisfied the criteria for testing after 5-74 additional training sessions at 5.6 mg/kg. The total number of training sessions required for each monkey to pass the test criteria were 230, 234, 250, and 299.
In monkeys not receiving nicotine treatment, mecamylamine dose-dependently increased the percentage of responses on the mecamylamine lever up to 98% at the training dose (5.6 mg/kg subcutaneously; Fig. 1, top  right) , whereas saline produced no responses on the mecamylamine lever (Fig. 1, top right, square) . The ED 50 value (95% confidence limits) of mecamylamine to produce discriminative stimulus effects was 2.95 mg/kg (1.27-6.83 mg/kg). When the training dose (5.6 mg/kg) of mecamylamine was studied over time, mecamylaminelever responding varied significantly as a function of time (F 14,28 = 8.00, P < 0.001). From 30 to 90 min, mecamylamine-lever responding was at least 98% (Fig. 2,  top) . Mecamylamine-lever responding was at least 73% up to 230 min after mecamylamine administration and then decreased to 28-33% by 270-310 min. The control rates of responding for individual monkeys were 1.54, 1.90, 2.25, and 2.51 responses/s. The response rate did not vary significantly as a function of mecamylamine dose (1-5.6 mg/kg) or as a function of time after the training dose (P > 0.05).
The effects of nicotine alone and in combination with mecamylamine
When administered alone, nicotine base (1-3.2 mg/kg) produced a maximum of 4% mecamylamine-lever responding and did not significantly alter the response rate (data not shown). Nicotine base, up to 5.6 mg/kg in nicotine-treated and 10 mg/kg in untreated monkeys, did not alter the discriminative stimulus effects of mecamylamine in either discrimination (Fig. 3 , top left and right, respectively). When tested in combination with mecamylamine (5.6 mg/kg) in untreated monkeys, nicotine base dose-dependently decreased the response rate to 33% of control at a dose of 10 mg/kg of nicotine (Fig. 3,  bottom right) . The ED 50 value (95% confidence limits) for nicotine to decrease the rate of responding was 8.37 mg/kg (1.77-39.5 mg/kg).
The effects of hexamethonium in nicotine-treated and untreated monkeys
Hexamethonium dose-dependently increased responding on the mecamylamine lever in nicotine-treated and untreated monkeys (Fig. 4 , top left and right, respectively). A dose of 10 mg/kg hexamethonium produced 94% mecamylamine-lever responding in nicotine-treated monkeys. Among the untreated monkeys, three of four monkeys responded greater than 95% on the mecamylamine lever at 17.8 and 32 mg/kg hexamethonium, and one of four monkeys responded a maximum of 5% on the mecamylamine lever, resulting in a group average maximum of 76% at 32 mg/kg hexamethonium (Fig. 4, top  right) . The ED 50 values (95% confidence limits) of hexamethonium to produce mecamylamine-lever responding were 5.89 mg/kg (3.50-9.94 mg/kg) in nicotine-treated monkeys and 9.36 mg/kg (2.50-35.0 mg/kg) in untreated (control) monkeys. Hexamethonium did not significantly modify the response rate at the doses tested (Fig. 4, bottom) .
Discontinuation of nicotine treatment
At the end of the study, monkeys that were receiving continuous nicotine treatment were tested on consecutive days immediately before and after the nicotinecontaining osmotic minipumps were removed. All five monkeys responded primarily on the saline-associated lever 1 day before pump removal (Fig. 5 ). However, 1 day after the removal of the osmotic minipumps three of the five monkeys responded, at least partially, on the mecamylamine lever (46, 65, and 87%). The relationship between days of nicotine deprivation and the amount of mecamylamine-lever responding differed among these three monkeys; mecamylamine-lever responding lasted only 1 day in one monkey (Fig. 5, triangles) , 2 days in another monkey (Fig. 5, diamonds) , and persisted for the duration of the experiment (4 days) in the third monkey ( Fig. 5, inverted triangles) . Two of the five monkeys responded predominantly on the saline lever before and after pump removal. Discontinuation of continuous nicotine administration did not modify the response rate over time (data not shown) as compared with the saline control, determined during continuous nicotine treatment. Moreover, systematic changes in directly observable behavior that might be indicative of a nicotine withdrawal syndrome, either after mecamylamine administration during nicotine treatment or after abrupt discontinuation of nicotine treatment, were not consistently observed in all monkeys during any of the experiments reported here. Mecamylamine produced ptosis and paleness in the face; however, these effects did not appear to differ in nicotine-treated versus untreated monkeys.
Discussion
The noncompetitive nAChR antagonist mecamylamine was established as a discriminative stimulus in one group of monkeys not receiving continuous nicotine treatment and in another group of monkeys receiving 5.6 mg/kg/day nicotine base. Monkeys receiving continuous nicotine could discriminate a smaller dose of mecamylamine compared with monkeys not receiving continuous nicotine (1.78 and 5.6 mg/kg, respectively). The peripheral nAChR antagonist hexamethonium substituted for mecamylamine in both groups. Nicotine was unable to attenuate the effects of mecamylamine in either group.
There were individual differences in test performance when continuous nicotine treatment was abruptly discontinued. Three of five monkeys switched their response choice from the saline-associated lever to the mecamylamine-associated lever after 1 day of discontinuation, whereas two other monkeys continued to respond on the saline lever throughout 4 days of nicotine deprivation. Although the performance of some monkeys is consistent with antagonism of nicotine and nicotine withdrawal, the inability of nicotine to attenuate the mecamylamine discriminative stimulus demonstrates a limitation of the assay in assessing the withdrawalmodifying effects of nAChR agonists.
Drug discrimination is useful in examining antagonistinduced withdrawal from opioids, benzodiazepines, and cannabinoids (Li et al., 2011) . Here, the nAChR antagonist mecamylamine was established as a discriminative stimulus in rhesus monkeys receiving continuous subcutaneous administration of 5.6 mg/kg/day nicotine. Two outcomes suggested that the discrimination in nicotinetreated monkeys was related to withdrawal. First, nicotine-treated monkeys were more sensitive to the discriminative stimulus effects of mecamylamine inasmuch as a larger dose of mecamylamine was needed to maintain stimulus control over behavior in monkeys not receiving nicotine treatment. Second, abrupt discontinuation of nicotine treatment substituted for the mecamylamine discriminative stimulus in a subset of monkeys. These results notwithstanding, nicotine was unable to attenuate mecamylamine-induced nicotine withdrawal. In contrast, a variety of drugs, including the dependence-inducing drug, modify the discriminative stimulus effects of their respective antagonists in monkeys receiving chronic treatment with opioids, benzodiazepines, or cannabinoids (Li et al., 2011) . The failure of nicotine to modify the effects of mecamylamine limits the utility of the current assay as compared with other withdrawal-related discrimination assays.
The daily dose (5.6 mg/kg) of nicotine and the method of drug delivery (continuous administration through an osmotic minipump) were selected not only on the basis of previous studies but also on the basis of the limits of dosing with a single osmotic minipump. Robust nicotine withdrawal has been observed in rats treated with 3.2 mg/kg/day nicotine, a dose ∼ 10-fold higher than a training dose for nicotine discrimination in rats (i.e. 0.4 mg/kg; Stolerman et al., 1984) . In nonhuman primates, doses of 1-2 mg kg/day have been studied (Howell, 1995; Grove et al., 2001) , which are similar to the dose of nicotine that has been used as a training dose (1.78 mg/ kg) for drug discrimination in rhesus monkeys (Cunningham et al., 2012) . The dose chosen for daily treatment in rhesus monkeys (5.6 mg/kg/day nicotine base) was larger than the training dose of nicotine previously used in rhesus monkeys, but was limited by the Mecamylamine discrimination in rhesus monkeys Cunningham et al. 301 maximum concentration and volume allowable in most commercially-available osmotic minipumps.
In nicotine-treated monkeys, the failure of additional nicotine to attenuate, or surmount, the discriminative stimulus effects of mecamylamine is most likely due to a noncompetitive interaction. Although enhanced sensitivity to mecamylamine as a function of chronic nicotine treatment has been reported here and elsewhere (Hildebrand et al., 1997; Vann et al., 2006) , the extent to which additional, acute administration of nicotine prevents or reverses mecamylamine-induced nicotine withdrawal is currently unclear. The results of several drug discrimination studies suggest that nicotine is unable to surmount the antagonism by mecamylamine (Jutkiewicz et al., 2011; Cunningham et al., 2012) . Among alternative nAChR antagonists suitable for behavioral studies, dihydro-β-erythroidine is a competitive nAChR antagonist (Williams and Robinson, 1984) . However, dihydro-βerythroidine produced limited (i.e. two-fold) antagonism of a nicotine-discriminative stimulus in rhesus monkeys up to doses that could safely be studied (Cunningham et al., 2012) . This is in contrast to the marked antagonism produced by mecamylamine in the same nicotine discrimination assay. Sensitivity to the effects of dihydroβ-erythroidine might have been enhanced in nicotinetreated animals, not only because of precipitated withdrawal, but also because chronic nicotine treatment upregulates nAChRs (Barik and Wonnacott, 2009 ). However, dihydro-β-erythroidine was not studied here because of concerns about toxicity.
Nicotine treatment appears to have increased the potency of mecamylamine to produce discriminative stimulus effects. Monkeys receiving continuous nicotine treatment were able to discriminate a dose (1.78 mg/kg) of mecamylamine 0.5 log unit smaller than the dose (5.6 mg/kg) discriminated by monkeys not receiving continuous nicotine. A similar difference in potency has been reported in rhesus monkeys discriminating the benzodiazepine antagonist flumazenil in the presence versus the absence of daily diazepam treatment (Gerak and France, 1999) . In contrast, the potency of naltrexone as a discriminative stimulus is markedly (i.e. 100-fold) different in morphine-treated versus untreated pigeons (Valentino et al., 1983) . Moreover, monkeys not receiving continuous nicotine treatment required more time to acquire mecamylamine discrimination than nicotinetreated monkeys. Increased sensitivity to the effects of an antagonist, resulting from continuous treatment with a pharmacologically related agonist, is due to the displacement of agonist binding as well as the dose of the agonist and the magnitude of dependence insofar as increased sensitivity to the antagonist is due to agonist withdrawal. In contrast, the effects of an antagonist in drug-naive animals are mediated by changes in endogenous tone at the primary site of action or by actions of the antagonist at the secondary site(s), especially at relatively large doses. Although the pharmacology of the mecamylamine discriminative stimulus is not further described here, a mecamylamine discrimination established elsewhere in rats had a pharmacologic profile consistent with actions at both nACh and N-methyl-Daspartate receptors (Garcha and Stolerman, 1993) . The training dose of mecamylamine in rats (3.5 mg/kg) was much larger than the dose of mecamylamine (0.1 mg/kg mecamylamine) that antagonizes the discriminative stimulus effects of nicotine (Stolerman et al., 1983) .
The relative potency of mecamylamine to produce multiple effects in rats and monkeys facilitates interpretation of the current data. The training dose of mecamylamine in rats not receiving nicotine treatment was 3.5 mg/kg and the dose of mecamylamine required to produce full substitution was 5.6 mg/kg (Garcha and Stolerman, 1993) . Smaller doses (0.1 mg/kg) of mecamylamine antagonized the effects of nicotine in rats (Stolerman et al., 1983) . In rhesus monkeys, a dose of 0.32 mg/kg mecamylamine significantly antagonized a nicotine discriminative stimulus (Cunningham et al., 2012) , demonstrating that the relative potency of mecamylamine to antagonize nicotine and to maintain Mecamylamine discrimination in rhesus monkeys Cunningham et al. 303 stimulus control over behavior in the absence of nicotine treatment did not differ between rhesus monkeys and rats. Overall, these data strengthen the notion that 5.6 mg/kg mecamylamine is near the smallest dose that can be discriminated without nicotine treatment and provide further evidence that discrimination of mecamylamine at a smaller dose (1.78 mg/kg) in nicotinetreated monkeys is related to antagonism of nicotine.
The noncompetitive nAChR antagonist hexamethonium substituted for the mecamylamine discriminative stimulus in both nicotine-treated and untreated monkeys, suggesting that nAChRs mediated both discriminations. Hexamethonium is a quaternary compound that does not readily cross the blood-brain barrier and is used clinically as an antihypertensive at a dose of 1 mg/kg (Paton and Zaimis, 1974) . Therapeutic effects result from the antagonism of ganglionic nAChRs. In rhesus monkeys, doses (7-10 mg/kg) of hexamethonium larger than those used clinically and similar to those used here were reported to decrease the mean arterial blood pressure (Dews and Herd, 1974; Gaide et al., 1980) . If the pharmacological mechanism(s) underlying the discriminative stimulus and cardiovascular effects of hexamethonium in rhesus monkeys is the same, then nAChRs located outside the brain mediate the discriminative stimulus effects of mecamylamine. However, the fact that doses of hexamethonium larger than 10 mg/kg were needed to fully substitute for mecamylamine in the absence of nicotine treatment might reflect penetration into and actions at receptors in the brain.
In agonist-dependent animals discriminating an antagonist, abrupt discontinuation of agonist treatment can lead to a time-related increase in withdrawal and a corresponding switch in responding from the lever associated with vehicle, or the absence of withdrawal, to the lever associated with the antagonist, or the presence of withdrawal (Becker et al., 2008; Stewart and McMahon, 2010) . Discontinuation of nicotine treatment (5.6 mg/kg/day) resulted in a switch from the saline lever to the mecamylamine lever in three of five rhesus monkeys. In two monkeys, responding on the mecamylamine lever decreased over time. The effects of nicotine deprivation in the other monkey might also have been time-limited; however, the deprivation period did not extend beyond four consecutive days. Discontinuation of nicotine treatment did not mimic the effects of mecamylamine during nicotine treatment in all monkeys. At a minimum, there are differences in the magnitude of discriminative stimulus effects between the two conditions, and perhaps also a difference in the quality such that discriminative stimulus effects are unrelated to nicotine withdrawal for at least one of the conditions. In summary, the discriminative stimulus effects of mecamylamine appeared to change both quantitatively and qualitatively as a function of nicotine treatment. Further, discontinuation of nicotine treatment produced mecamylamine-lever responding in some, but not all, monkeys. Although the overall profile suggests that mecamylamine discrimination in nicotine-treated monkeys is related to nicotine withdrawal, nicotine was unable to attenuate the discriminative stimulus effects of mecamylamine. The noncompetitive nature of the interaction between mecamylamine and nicotine at nAChRs appears to limit the combined use of mecamylamine and drugs that bind to the same site as nicotine as a strategy for assessing the neuropharmacology of nicotine dependence. 
Days of nicotine deprivation
Time-course of mecamylamine-like discriminative stimulus effects after discontinuation of continuous nicotine (Nic) treatment in individual monkeys. Horizontal axis: time in days. Vertical axis: percentage of responding on the mecamylamine lever.
